STOCK TITAN

Voyager Therapeutics (VYGR) Revenue by Year

VYGR NASDAQ

Voyager Therapeutics, Inc. generated $40.4M in revenue in fiscal year 2025. This represents a decrease of 49.5% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $25.1M in revenue. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Voyager Therapeutics, Inc. has filed alongside them.

FY2025 annual
Revenue $40.4M
YoY -49.5%
5Y CAGR -25.1%
10Y CAGR +8.8%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

VYGR Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-K
Revenue$25.1M$40.4M-49.5%$80.0M-68.0%$250.0M+511.2%$40.9M+9.3%$37.4M-78.1%$171.1M+63.9%$104.4M+1270.1%$7.6M-24.8%$10.1M-28.7%$14.2M-18.0%$17.3MN/A

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

VYGR Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$4.0M-70.0%$3.2M-39.1%$2.6M-59.9%$15.3M+144.3%$13.4M-45.7%$5.2M-82.4%$6.5M-66.8%$6.3M-93.0%$24.6M+433.8%$29.6M+509.5%$19.5M-87.0%$90.1M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Voyager Therapeutics, Inc. financials

Frequently Asked Questions

Voyager Therapeutics, Inc. generated $40.4M in revenue in fiscal year 2025.

Voyager Therapeutics, Inc. (VYGR) revenue fell by 49.5% year over year, from $80.0M to $40.4M in fiscal year 2025.

Voyager Therapeutics, Inc. (VYGR) reported $25.1M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Voyager Therapeutics, Inc. (VYGR) reported $4.0M in revenue in Q3 2026. This represents a decrease of 70.0% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Voyager Therapeutics, Inc. (VYGR) reported on that line in every period on record.